Get the Stockscreener App
2.15
3.15%
-0.07
After Hours:
2.18
0.03
+1.40%
Annovis Bio Inc stock is traded at $2.15, with a volume of 452.66K.
It is down -3.15% in the last 24 hours and down -22.38% over the past month.
Annovis Bio Inc is a late-stage clinical drug platform company addressing neurodegeneration, including Alzheimer's disease (AD) and Parkinson's disease (PD). The Company is developing its product candidate, buntanetap, a synthetically produced, orally administered, brain-penetrant small molecule designed to treat AD, PD, and potentially other chronic neurodegenerative diseases by inhibiting the synthesis of neurotoxic proteins and TDP43, which contribute to neurodegeneration and reduced axonal transport. Its pipeline includes buntanetap for chronic neurodegeneration, including AD, PD, and PDD, as well as in certain combination therapies, ANVS405 for acute neurodegeneration, and ANVS301 for AD.
See More
Previous Close:
$2.22
Open:
$2.2
24h Volume:
452.66K
Relative Volume:
1.04
Market Cap:
$60.96M
Revenue:
-
Net Income/Loss:
$-28.85M
P/E Ratio:
-1.5334
EPS:
-1.4021
Net Cash Flow:
$-25.62M
1W Performance:
-19.48%
1M Performance:
-22.38%
6M Performance:
+9.14%
1Y Performance:
+16.22%
1-Day Range:
$2.11
$2.24
1-Week Range:
$2.11
$2.72
52-Week Range:
$1.11
$5.50
Annovis Bio Inc Stock (ANVS) Company Profile
Name
Annovis Bio Inc
Sector
Industry
Phone
484-875-3192
Address
101 LINDENWOOD DRIVE, SUITE 225, MALVERN, PA
Compare ANVS vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANVS
Annovis Bio Inc
|
2.15 | 62.95M | 0 | -28.85M | -25.62M | -1.4021 |
VRTX
Vertex Pharmaceuticals Inc
|
453.74 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
756.73 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.16 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
692.83 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
147.60 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Annovis Bio Inc Stock (ANVS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-10-25 | Downgrade | D. Boral Capital | Buy → Hold |
| Oct-25-24 | Upgrade | Maxim Group | Hold → Buy |
| Dec-29-23 | Initiated | Canaccord Genuity | Buy |
| Jul-07-21 | Reiterated | Maxim Group | Buy |
Annovis Bio Inc Stock (ANVS) Latest News
Annovis Partners With NeuroRPM to Add AI Monitoring in PD Study - MyChesCo
Annovis Bio, Inc. Files Form 8-K with NYSE Listing and Corporate Information for March 23, 2026 - Minichart
Annovis Bio CFO departs, CEO appointed as acting CFO By Investing.com - Investing.com Canada
Biopharmaceutical company Annovis Bio Inc announced that its CEO Maria Maccecchini will temporarily serve as CFO until the company finds a permanent replacement. - Bitget
Annovis Bio's Mark Guerin departs as CFO; Maria Maccecchini to serve as Acting CFO - TradingView
CFO departs Annovis Bio (ANVS) as CEO Maria Maccecchini takes acting finance role - Stock Titan
Annovis Bio Secures Full Patent Protection for New Crystal Form of Alzheimer’s Drug Buntanetap - MSN
Annovis Reports 2025 Results, Advances Buntanetap Trials - MyChesCo
If You Invested $1,000 in Annovis Bio Inc (ANVS) - Stock Titan
ANVS SEC FilingsAnnovis Bio Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Market Rankings: Will Annovis Bio Inc stock recover after earnings2026 Chart Watch & High Conviction Buy Zone Picks - baoquankhu1.vn
Meme Stocks: Will Annovis Bio Inc benefit from rising consumer demand2026 Short Interest & Free Expert Verified Stock Movement Alerts - baoquankhu1.vn
Annovis Bio Publishes Data on New Crystal Form of Lead Alzheimer’s Drug - MSN
NeuroRPM Partners with Annovis for Parkinson's Disease Monitoring - Intellectia AI
Annovis Bio partners with NeuroRPM for Parkinson’s trial monitoring By Investing.com - Investing.com India
Annovis Bio partners with NeuroRPM for Parkinson’s trial monitoring - Investing.com
NeuroRPM to Deploy AI-Enabled Digital Biomarker Monitoring for Annovis Bio's Parkinson's Disease Clinical Trial - markets.businessinsider.com
Neurorpm To Deploy Ai-Enabled Digital Biomarker Monitoring For Annovis Bio's Parkinson's Disease Clinical Trial - TradingView
Annovis Partners with NeuroRPM to Deploy AI-Powered Digital Biomarker Technology in Parkinson's Disease Study - The Manila Times
Wearables track Parkinson's symptoms in Annovis drug study - Stock Titan
Annovis Stock Rises After Company Confirms Meeting With Regulators To Discuss Drug In Treating Parkinson's Disease Dementia - MSN
Annovis Bio CEO to Present at H.C. Wainwright Global Investment Conference - MSN
Shorts Report: Is Annovis Bio Inc stock forming a triangle pattern2026 Gainers & Real-Time Volume Analysis Alerts - baoquankhu1.vn
Chart Watch: Should you avoid Annovis Bio Inc stock right now2026 Performance Recap & Low Risk High Win Rate Picks - baoquankhu1.vn
ANVS Technical Analysis & Stock Price Forecast - Intellectia AI
Annovis Bio Reports Promising Biomarker Results Showing Anti-Inflammatory, Neuroprotective Effects of Buntanetap in Alzheimer’s Patients - MSN
Phase 3 trial push deepens 2025 loss at Annovis Bio (NYSE: ANVS) - Stock Titan
Annovis Bio shares are trading higher. The company reported Q4 financial results.Annovis Bio (NYSE:ANVS) - Benzinga
Annovis Provides Corporate Updates and Reports Fiscal Year 2025 Financial Results - Bitget
Annovis Bio, Inc. Announces Business Updates and Financial Results for Fiscal Year 2025, Highlighting Pivotal Advances in Buntanetap Development for Neurodegenerative Diseases - Quiver Quantitative
Annovis Bio Q4 EPS $(0.39) Misses $(0.34) EstimateAnnovis Bio (NYSE:ANVS) - Benzinga
Alzheimer’s oral drug buntanetap enters pivotal trial, 3‑year PD study - Stock Titan
Annovis Bio (ANVS) Stock Analysis Report | Financials & Insights - Benzinga Japan
Annovis Bio to present buntanetap clinical data at AD/PD 2026 conference - MSN
Annovis Bio (NYSE: ANVS) outlines late-stage Alzheimer’s and Parkinson’s program - Stock Titan
Annovis Bio’s Buntanetap: Advancing Clinical Development for Alzheimer’s and Parkinson’s Disease with Novel Multi-Targeted Approach 33 - Minichart
Annovis Bio (NYSE:ANVS) Releases Earnings Results, Misses Expectations By $0.08 EPS - MarketBeat
Annovis Bio 10-K: Net loss $28.9M; Cash $19.5M, runway into Q3 2026 - TradingView
Annovis Bio Reports Progress in Clinical Trials and Improved Financial Position - MSN
Annovis Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Annovis Bio (ANVS) Projected to Post Quarterly Earnings on Friday - MarketBeat
Annovis Bio, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
ANVS|Annovis Bio Inc|Price:2.490|Chg%:-0.09 - TradingKey
Published on: 2026-03-11 14:44:25 - baoquankhu1.vn
Annovis Bio to Present Buntanetap Clinical Data at AD/PD 2026 Conference - MyChesCo
Support Test: Is Annovis Bio Inc. stock technically oversold2026 WrapUp & Technical Confirmation Trade Alerts - baoquankhu1.vn
Annovis Bio Secures NYSE Approval to Regain Compliance with Listing Standards - MSN
Momentum Shift: What makes Annovis Bio Inc stock attractive todayM&A Rumor & Fast Gain Stock Tips - baoquankhu1.vn
Annovis Bio Stock Price Drops 8.5%What's Next? - National Today
Annovis Bio (NYSE:ANVS) Stock Price Down 8.5%What's Next? - MarketBeat
Annovis CEO eyes spring breakthrough for Alzheimer’s drug - Longevity.Technology
Annovis Bio Inc Stock (ANVS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.04%
0.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):